Back to Search Start Over

Potential Conscientious Objection to mRNA Technology as Preventive Treatment for COVID-19

Authors :
Patrick Provost
Nicolas Derome
Christian Linard
Bernard Massie
Jean Caron
Source :
International Journal of Vaccine Theory, Practice, and Research. 2:445-454
Publication Year :
2022
Publisher :
Institute for Vaccine Theory, Practice, and Research, 2022.

Abstract

In the context of mass vaccination campaigns, the most widely used vaccines in Western countries are based on messenger RNA (mRNA). Some countries have imposed mandatory vaccination and many others have required a vaccination passport to access public transportation and many activities, producing systemic discrimination, social exclusion, segregation, and stigmatization against non-vaccinated individuals. This paper aims to present several scientific uncertainties on which, conscientious objectors to mRNA injections as a preventive treatment for COVID-19, could rely. Scientific data are presented on mRNA vaccines, which consist in mRNAs wrapped in lipid nanoparticles. Never used as a prophylactic drug, artificial mRNAs delivered to our cells forces them to express, against their nature, a biologically active viral protein. Unlike a drug produced in a pharmaceutical factory and formulated at a known dose and a well-defined protein product profile, the mRNA vaccine acts as a pro-drug encoding for the viral Spike protein of the virus to be produced by our own cells; both the dose and the quality of the proteins produced are unknown. We also ignore the distribution of the lipid nanoparticles carrying this mRNA in our body. We consider that the “conscientious objection” raised by the above considerations is a reason enough to refuse mRNA vaccines or similar technologies as a preventive treatment against COVID-19.

Details

ISSN :
27665852
Volume :
2
Database :
OpenAIRE
Journal :
International Journal of Vaccine Theory, Practice, and Research
Accession number :
edsair.doi...........fd591d60098adbc6cc4ea99ec4f69669
Full Text :
https://doi.org/10.56098/ijvtpr.v2i2.41